文献速递前列腺癌

循环肿瘤细胞表型预测转移性去势敏感性前列腺癌的去势抵抗时间

Phenotypes of circulating tumour cells predict time to castration resistance in metastatic castration-sensitive prostate cancer.
PubMed 文献 · BJU Int · 2019-02-12

该研究纳入108例新诊断高容量转移性去势敏感性前列腺癌患者,采用CanPatrol技术检测基线循环肿瘤细胞(CTC)并分类上皮、双表型和间质表型。中位随访24个月,间质型CTC阳性患者进展至去势抵抗性前列腺癌的比例更高、中位时间更短,CTC表型是唯一独立预后因素。

要点

  • 基线间质型CTC阳性提示标准ADT有效时间缩短。
  • 间质型CTC阳性患者中位至CRPC时间10.5个月。
  • CTC表型是CSPC进展至CRPC的独立预后因素。

核心结论

  • 基于EMT表型的基线CTC特征可预测新诊断转移性CSPC患者标准ADT的有效期。

研究设计与样本

  • 研究纳入108例新诊断高容量转移性CSPC患者,采用CanPatrol技术检测基线CTC并分类上皮、双表型和间质表型。

主要发现

  • 中位随访24个月,90例(83.3%)进展至CRPC,93例(86.1%)可检测到CTC,CTC中位数为4。
  • 间质型CTC阳性患者进展至CRPC的比例为93.1%,高于CTC阳性/间质型CTC阴性患者的71.4%和CTC阴性患者的73.3%(P = 0.013)。
  • 间质型CTC阳性患者中位至CRPC时间为10.5个月,短于CTC阳性/间质型CTC阴性患者的18.0个月和CTC阴性患者的14.0个月(P = 0.003)。
  • 多因素Cox回归分析提示CTC表型是影响CSPC进展至CRPC的唯一独立预后因素。

临床怎么用

  • 基线CTC表型检测有助于对转移性CSPC患者进行预后分层和咨询。
  • 间质型CTC阳性患者可考虑更密切监测或临床试验设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To identify biomarkers that predict the response to standard androgen deprivation therapy (ADT) of patients newly diagnosed with metastatic castration-sensitive prostate cancer (CSPC) in order to improve therapeutic decision-making, and to investigate whether the characterization of baseline circulating tumour cells (CTCs) would predict the effective period of standard ADT. MATERIALS AND METHODS: The study included 108 patients newly diagnosed with high-volume metastatic CSPC. Enumeration and characterization of patients' baseline CTCs (CTCs+ and CTCs-, indicating detectable and undetectable CTCs, respectively) were performed using the CanPatrol technique, which detects markers of the epithelial to mesenchymal transition (EMT) in CTCs, and classifies CTCs into epithelial, biophenotypic and mesenchymal phenotypes. RESULTS: After a median follow-up of 24 months, 90 patients (83.3%) progressed to castration-resistant prostate cancer (CRPC), 93 patients (86.1%) had detectable CTCs, and the median number of CTCs was 4. The rate of progression to CRPC was significantly higher for patients with mesenchymal CTCs+ than for patients with CTCs+/mesenchymal CTCs- and CTCs- (93.1% vs 71.4% and 73.3%; P = 0.013). The median time to CRPC for patients with mesenchymal CTCs+ was significantly shorter than for those with CTCs+/mesenchymal CTCs- and CTCs- (10.5 months vs 18.0 and 14.0 months; P = 0.003). Multivariate Cox regression analysis suggested that the CTC phenotype was the only independent prognostic factor influencing the progression of disease from CSPC to CRPC. CONCLUSIONS: Characterization of baseline CTCs according to the EMT phenotype predicted the effective period of standard ADT for patients newly diagnosed with metastatic CSPC. These findings are important for counselling patients and designing clinical trials.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Yang YJ, Kong YY, Li GX, et al. Phenotypes of circulating tumour cells predict time to castration resistance in metastatic castration-sensitive prostate cancer. BJU Int. 2019. PMID: 30536520. doi:10.1111/bju.14642

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。